A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
about
Identification of new epilepsy treatments: issues in preclinical methodologyBasic mechanisms of catastrophic epilepsy -- overview from animal modelsHarnessing the power of metabolism for seizure prevention: focus on dietary treatmentsFinding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic targetPathogenesis and new candidate treatments for infantile spasms and early life epileptic encephalopathies: A view from preclinical studiesRapamycin attenuates the development of posttraumatic epilepsy in a mouse model of traumatic brain injuryVigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complexEfficacy and tolerability of the galanin analog NAX 5055 in the multiple-hit rat model of symptomatic infantile spasms.CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms.The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile sThe interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway.Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction.The mTOR inhibitor rapamycin has limited acute anticonvulsant effects in mice.Evidence for mTOR pathway activation in a spectrum of epilepsy-associated pathologies.Rapamycin reverses status epilepticus-induced memory deficits and dendritic damage.mTOR signaling in epilepsy: insights from malformations of cortical developmentEpilepsy as a neurodevelopmental disorder.Rapamycin attenuates aggressive behavior in a rat model of pilocarpine-induced epilepsy.Rapamycin down-regulates KCC2 expression and increases seizure susceptibility to convulsants in immature rats.Rapamycin has age-, treatment paradigm-, and model-specific anticonvulsant effects and modulates neuropeptide Y expression in rats.Impaired autophagy in neurons after disinhibition of mammalian target of rapamycin and its contribution to epileptogenesis.Rapamycin has paradoxical effects on S6 phosphorylation in rats with and without seizures.Issues for new antiepilepsy drug development.Is mTOR inhibition a systemic treatment for tuberous sclerosis?Mammalian target of rapamycin (mTOR) inhibition: potential for antiseizure, antiepileptogenic, and epileptostatic therapy.A critical review of mTOR inhibitors and epilepsy: from basic science to clinical trials.Mammalian target of rapamycin (mTOR) pathways in neurological diseases.Epilepsy Mechanisms in Neurocutaneous Disorders: Tuberous Sclerosis Complex, Neurofibromatosis Type 1, and Sturge-Weber Syndrome.Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES).Vigabatrin monotherapy for infantile spasms.Novel animal models of pediatric epilepsy.Latest American and European updates on infantile spasms.Adrenocorticotropic hormone for the treatment of West Syndrome in children.mTOR inhibitors as a new therapeutic option for epilepsy.Recent advances in the pharmacotherapy of infantile spasms.Pathophysiology of epileptic encephalopathies.Pathogenetic mechanisms of focal cortical dysplasia.Autophagy and amino acid metabolism in the brain: implications for epilepsy.The role of autophagy in epileptogenesis and in epilepsy-induced neuronal alterations.mTOR inhibition in epilepsy: rationale and clinical perspectives.
P2860
Q24289140-9E59C12B-145D-479B-A58A-4B285AE6FD87Q26864346-D70C24EC-4CE6-4DAB-A977-4E1C42890358Q26991869-2DE333BF-FAA9-4D95-B6C4-2A9D4E951398Q27024547-ACD39670-EDCD-4AE3-B63F-23EEC35CC4B8Q27308052-049BC61D-F130-4745-B0B1-3341DDDC3C3BQ27319659-88837FFF-2182-45BE-BA7A-79B384291695Q28486250-DEE5AA10-5BB8-403E-B0E2-FF4AEC96E747Q30560643-038C9C1A-26C5-4DA0-AB38-9B486EBB8740Q30584190-98EB64F6-70BA-4918-9D29-1953343555B2Q34240602-40C1825A-FF14-490C-B110-12C69FF3D01DQ34261603-5C2FC413-A373-45AD-949B-BA25A91FC273Q34339959-42E5B8C1-F790-4D81-AA30-5D05FEC552CBQ34416405-8C6619FD-62B5-4744-BB9A-69B284176DE2Q34503246-11C5A18E-3F1F-4FA3-84C0-B8AF25E098A3Q34639033-CEA80D5F-1112-4B3B-A6AF-82468E3E53B1Q35245211-2868C010-78AC-4C28-AFEE-8BD4E1AC67B8Q35838099-E5F72D7F-1E85-4BF7-A4C3-6434F11A3922Q36019947-A506616E-CB83-4F19-A59D-FC8072C6CF15Q36110085-DBF166F5-D7B8-4710-BE5D-6884C285DB43Q36395227-48AD8A36-8DA4-4788-A3F7-D136418A2D1BQ36410001-E7480BED-9C28-4F87-B032-008707287716Q36411217-5C77AEC9-C19E-4568-85C1-618EE403390DQ37164052-8F7A9CF6-83D3-48A7-B938-0FD76DDAE839Q37359517-F703DFFF-EDF9-4783-B963-3C84133BAFD7Q37419781-597FF1A9-9542-498A-A3AC-6D8B98814F11Q37419785-1C0ED670-8774-4904-947A-96F98147CF5EQ37432305-9C0CD5D2-79F2-4E66-A164-40A5C19907FEQ37707250-6F9AD097-8E33-44AB-95C0-FD6DAA122DA5Q37717421-29B717E0-2AF1-4E57-95D1-7BE2AB75CCA4Q37987986-045F1B8E-60F3-4FF8-A237-F663CFFD98ADQ37998957-B1E1D47C-D9C9-4B3A-ACE0-EA8DF3A31607Q38076086-048F25F1-723C-45C3-A55B-EBC5881AF4B5Q38100763-5D7A5076-4BDC-4278-8206-99D164918A62Q38112211-B3EFD84B-A3BD-430C-9C70-5024DB3C2C9DQ38185985-E56FEEB3-590D-4AF6-A332-69DAEE8D320AQ38191243-170452BB-901D-4C88-8E37-3E3B498CBE55Q38214869-A900FA9A-634A-48B9-83FD-1B02F1112659Q38242039-1252C1D9-BD05-414A-8320-6F65CDF9447FQ38248845-0C8394ED-E8C1-4F66-96FC-D3819EEEB8D4Q38336887-6D711F00-AB00-43B5-8F08-D96586BA2EC3
P2860
A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
@ast
A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
@en
type
label
A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
@ast
A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
@en
prefLabel
A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
@ast
A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
@en
P2093
P2860
P1476
A pulse rapamycin therapy for infantile spasms and associated cognitive decline.
@en
P2093
Antonietta Coppola
Aristea S Galanopoulou
Emmanuel Raffo
Stephen W Briggs
Tomonori Ono
P2860
P304
P356
10.1016/J.NBD.2011.03.021
P577
2011-04-12T00:00:00Z